Although the overall effect of the combinatory treatment was strongest in human breast cancer cells with more than 90% reduction in colony growth, the strength of the additional growth reduction between combinatory targeting and single PI3K-inhibitor treatment in HCC and CRC cells was comparable to human breast cancer cells (red bars; Supplementary Figure S21). Here, PIK3CA is linked to hepatocellular carcinoma.